CLINICAL TRIALS PROFILE FOR FLUOROMETHOLONE

All Clinical Trials for FLUOROMETHOLONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00707421 ↗	Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes	Completed	Funding for Research in Ophthalmology (FRO)	Phase 3	2005-07-01	Antiglaucoma medication have been shown to induce subclinical conjunctival inflammation in a considerable proportion of glaucoma patients. Today, trabeculectomy still remains the gold standard as surgical treatment of medically uncontrolled glaucoma disease. However, this procedure is associated with variable possible complications, of which subconjunctival fibrosis is the most frequent one. The latter results in a non-functional filtering bleb. As a consequence, either additional interventions such as laser suture lysis, needling, bleb revision or additional IOP-lowering medication is necessary. Previous studies demonstrated a benefit of the use of topical steroids postoperatively in reducing inflammation and subsequent subconjunctival fibrosis. In this perspective, we will prospectively explore the usefulness of topical NSAID or corticosteroid therapy preoperatively as compared to placebo in subjects scheduled for first-time trabeculectomy, without interrupting topical antiglaucoma therapy. This will allow us to determine wether the impact of longterm topical antiglaucoma therapy on subclinical conjunctival inflammation which possibly result in postoperative fibrosis and bleb failure can be reversed by anti-inflammatory medication before filtering surgery.
NCT00707421 ↗	Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes	Completed	Universitaire Ziekenhuizen Leuven	Phase 3	2005-07-01	Antiglaucoma medication have been shown to induce subclinical conjunctival inflammation in a considerable proportion of glaucoma patients. Today, trabeculectomy still remains the gold standard as surgical treatment of medically uncontrolled glaucoma disease. However, this procedure is associated with variable possible complications, of which subconjunctival fibrosis is the most frequent one. The latter results in a non-functional filtering bleb. As a consequence, either additional interventions such as laser suture lysis, needling, bleb revision or additional IOP-lowering medication is necessary. Previous studies demonstrated a benefit of the use of topical steroids postoperatively in reducing inflammation and subsequent subconjunctival fibrosis. In this perspective, we will prospectively explore the usefulness of topical NSAID or corticosteroid therapy preoperatively as compared to placebo in subjects scheduled for first-time trabeculectomy, without interrupting topical antiglaucoma therapy. This will allow us to determine wether the impact of longterm topical antiglaucoma therapy on subclinical conjunctival inflammation which possibly result in postoperative fibrosis and bleb failure can be reversed by anti-inflammatory medication before filtering surgery.
NCT00824811 ↗	Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel	Withdrawn	Allergan	Phase 2	2009-06-01	Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers.
NCT00824811 ↗	Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel	Withdrawn	M.D. Anderson Cancer Center	Phase 2	2009-06-01	Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers.

Clinical Trial Conditions for FLUOROMETHOLONE

Condition Name

Condition Name for FLUOROMETHOLONE
Intervention	Trials
Intraocular Pressure	4
Dry Eye Syndromes	2
Trichiasis	2
Eyelid Diseases	1

Condition MeSH

Condition MeSH for FLUOROMETHOLONE
Intervention	Trials
Dry Eye Syndromes	4
Keratoconjunctivitis Sicca	3
Eye Diseases	3
Keratoconjunctivitis	3

Clinical Trial Locations for FLUOROMETHOLONE

Trials by Country

Trials by Country for FLUOROMETHOLONE
Location	Trials
United States	4
China	4
Egypt	2
Ethiopia	2
Tunisia	1

Trials by US State

Trials by US State for FLUOROMETHOLONE
Location	Trials
Indiana	2
Pennsylvania	1
Utah	1

Clinical Trial Progress for FLUOROMETHOLONE

Clinical Trial Phase

Clinical Trial Phase for FLUOROMETHOLONE
Clinical Trial Phase	Trials
PHASE4	2
PHASE2	1
Phase 4	9

Clinical Trial Status

Clinical Trial Status for FLUOROMETHOLONE
Clinical Trial Phase	Trials
Completed	11
Not yet recruiting	5
Unknown status	3

Clinical Trial Sponsors for FLUOROMETHOLONE

Sponsor Name

Sponsor Name for FLUOROMETHOLONE
Sponsor	Trials
Zhongshan Ophthalmic Center, Sun Yat-sen University	2
University of Pennsylvania	2
Price Vision Group	2

Sponsor Type

Sponsor Type for FLUOROMETHOLONE
Sponsor	Trials
Other	37
Industry	4
U.S. Fed	1

Fluorometholone Clinical Trials, Market Analysis, and Future Outlook

Last updated: February 20, 2026

What is the Current Status of Fluorometholone in Clinical Trials?

Fluorometholone, a synthetic corticosteroid, is used primarily for ocular inflammation. It is marketed under various brand names globally and generally prescribed topical formulations for eye conditions.

As of 2023, no active clinical trials for new indications or formulations of fluorometholone are publicly registered on ClinicalTrials.gov or WHO ICTRP. The drug's development appears to be in maintenance or post-approval stages, with minimal ongoing investigation into novel uses or delivery systems.

Completed Trials and Approvals

• Indications: Treatment of anterior uveitis, allergic conjunctivitis, and postoperative inflammation.
• Regulatory Approvals: Approved in multiple countries, including the US, European Union, and Japan. Mainly marketed as ophthalmic suspension or ointments.

Ongoing and Future Trials

• No significant phase I-III trials underway specific to fluorometholone in recent registries.
• Some research explores combination therapies or new formulations, such as sustained-release implants, but these are in preclinical or early development phases.

Market Overview and Competitive Landscape

Market Size and Revenue

The global ophthalmic corticosteroid market, which includes fluorometholone, stood at approximately USD 1.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5% through 2030.

Key Market Players

• Bausch + Lomb: Offers fluorometholone in various formulations.
• Allergan (AbbVie): Historically marketed fluorometholone, currently focuses on broader ophthalmic drugs.
• Generic Manufacturers: Dominant producers, providing cost-effective options.

Distribution Channels and Regional Dynamics

• North America: Largest share, driven by advanced ophthalmology practices and higher healthcare spending.
• Europe: Significant market presence, with regulatory similarities to the US.
• Asia-Pacific: Fastest growth due to increasing ophthalmic disease prevalence and healthcare access expansion.

Competitive Advantages

Fluorometholone's low systemic absorption and minimal intraocular pressure elevation risk give it an edge over other corticosteroids. However, newer drugs with improved safety profiles and sustained-release formulations challenge its market position.

Market Trends and Projections

Trends

• Shift toward preservative-free formulations enhances patient safety.
• Development of sustained-release eye drops aims to reduce dosing frequency.
• Combination therapies integrating corticosteroids and NSAIDs gain popularity.

Projections

• The fluorometholone segment is expected to maintain steady demand over the next five years.
• Adoption of new delivery devices may boost overall market valuation.
• Regulator updates emphasizing safety mitigate certain corticosteroid classes' use; fluorometholone's safety profile sustains its relevance.

Key Drivers and Challenges

Drivers	Challenges
High prevalence of ocular inflammatory conditions	Competition from newer, safer corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs)
Established efficacy and safety profile	Limited innovation and formulation improvements
Cost-effectiveness and widespread availability	Regulatory pressure to reduce steroid-related side effects

Regulatory Environment and Future Outlook

The regulatory landscape remains stable, with most approvals based on existing safety data. Future regulatory changes that favor safer corticosteroid use or promote alternative treatments could impact fluorometholone's market share.

Investments in novel delivery platforms, such as sustained-release implants, could rejuvenate the drug's relevance. However, the absence of current clinical trials indicates that significant innovation is not imminent within the near term.

Key Takeaways

• No active clinical trials for fluorometholone are underway as of 2023.
• The drug maintains a steady market in ophthalmic corticosteroids, with a global valuation of USD 1.2 billion in 2022.
• Competition from newer therapies and formulation innovations limit rapid growth.
• Market growth will likely continue at a CAGR of around 5%, driven by regional demand increases.
• Innovation in delivery systems and regulatory pressures shape future prospects.

FAQs

1. Are there any ongoing clinical trials for fluorometholone? No, currently no active or publicly registered clinical trials for fluorometholone are underway.

2. What are the primary indications for fluorometholone? Treatment of ocular inflammation, including anterior uveitis, allergic conjunctivitis, and postoperative inflammation.

3. How does fluorometholone compare to other corticosteroids? It has a favorable safety profile with lower intraocular pressure elevation risks, making it suitable for sensitive patients.

4. What is the expected market growth for ophthalmic corticosteroids? The market is projected to grow at approximately 5% CAGR through 2030.

5. Are new formulations or delivery systems being developed for fluorometholone? There are early-stage research efforts focusing on sustained-release ocular implants, but none are in advanced clinical development.

References

[1] GlobalData. (2022). Ophthalmic corticosteroid market report.
[2] ClinicalTrials.gov. (2023). Registered clinical trials.
[3] MarketsandMarkets. (2023). Ophthalmic drugs market analysis.
[4] EMA. (2022). Ophthalmic corticosteroids approval database.
[5] WHO. (2023). International Clinical Trials Registry Platform.